Ray-tracing IOL modeling in AMD patients

Conferences|ARVO

Uwe Oberheide, MD, discusses the key findings of his virtual ARVO 2021 presentation on modeling of IOLs for patients with AMD by ray-tracing.

Uwe Oberheide, MD, of the University of Applied Sciences, Cologne, Germany, discusses the key findings from his virtual ARVO 2021 presentation on modeling of intraocular lenses (IOLs) for patients with age-related macular degeneration (AMD) by ray-tracing.

See more ARVO content

Related Videos
Related Content

Nanoscope Therapeutics announces positive topline results from Phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

March 31st 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

COPHy 2023: Traveling the path to new restorative therapies

March 24th 2023

Study examines frequency of retinopathy in patients diagnosed with type 2 diabetes mellitus

March 24th 2023

Nanoscope Therapeutics announces positive topline results from Phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

March 31st 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

COPHy 2023: Traveling the path to new restorative therapies

March 24th 2023

Study examines frequency of retinopathy in patients diagnosed with type 2 diabetes mellitus

March 24th 2023

Nanoscope Therapeutics announces positive topline results from Phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa

March 31st 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

COPHy 2023: Traveling the path to new restorative therapies

March 24th 2023

Study examines frequency of retinopathy in patients diagnosed with type 2 diabetes mellitus

March 24th 2023
© 2023 MJH Life Sciences

All rights reserved.